GMED logo

Globus Medical, Inc. GMED

HealthcareMedical - DevicesNYSE📅 Scored March 7, 2026
Price at analysis: $87.57
Crucible Score
63.5
B-
Quality × Value Composite
KQI — Quality
59.7
C+
Fundamental Quality Index
KVI — Value
68.2
B-
Valuation Attractiveness Index
Crucible Verdict — GMED

Globus Medical shows solid growth momentum with an 84 Growth Profile score, but GMED suffers from weak competitive positioning reflected in its 48 Moat Durability and 45 Management Effectiveness ratings. The stock trades at a modest 9% discount to fair value despite strong earnings execution under CEO Demski. Growth sustainability remains questionable given the company's limited defensive characteristics in the competitive medical device landscape.

— Kal, Kaladin Capital Intelligence

◆ KQI Quality Dimensions

Financial Quality
77.5
Growth Profile
83.6
Moat Durability
47.6
Management Effectiveness
45.3
Diversification & Resilience⚠
42.0
Market Position
60.0
Weakest dimension: Diversification & Resilience (42.0)

◆ KVI Value Dimensions

DCF Margin of Safety
57.9
FCF Yield & Cash Returns
50.8
Relative Valuation
83.8
Growth-Adjusted Value
81.2
Historical Valuation
92.1
Macro Context
60.3

◆ DCF Valuation Scenarios

Bear Case
$62.18
Base Case
$95.42
Bull Case
$141.63
Price at Analysis
$87.57
ScenarioFair ValueRev CAGR (5yr)Terminal MarginWACC
🔴 Bear$62.186.0%18.0%10.1%
🟢 Base$95.429.0%21.0%9.3%
🟢 Bull$141.6312.0%24.0%8.6%
Key Assumptions: GMED has shown strong revenue growth driven by the NuVasive merger (revenue nearly tripled over 5 years), but organic growth is moderating toward high-single-digits. Operating margins have been volatile (8-22%) as the company integrates acquisitions; base case assumes gradual margin normalization to ~21% as synergies are realized. WACC uses 5.5% ERP given healthcare device sector stability, with tax rate normalized at 18% reflecting historical range excluding one-time items.

◆ Financial Snapshot

Profitability

Gross Margin67.4%
Operating Margin16.3%
Net Margin18.3%
ROIC7.6%
ROE9.1%

Balance Sheet

Balance SheetCR: 4.26
Cash ConversionFCF/EPS: 1.08x
Capital IntensityCapex/Rev: 5.6%
Altman Z-Score11.56 (Safe)
Piotroski F-Score8/9 (Strong)

Growth

Revenue CAGR32.3% CAGR
Earnings CAGR37.8% CAGR
Growth ConsistencyCV: 0.92
Segment Breadth4/4 growing (100%)
Quarterly TrendRev↑, Margin↑, WC↓, Exp↓
Earnings CredibilityTends to Beat

◆ Revenue Breakdown — FY2024

By Segment

Spine93.9%
Emerging Technology6.1%

By Geography

UNITED STATES100.0%
Total Revenue
$2.4B
Fiscal Year 2025

◆ Analyst Consensus & Leadership

Analyst Price Targets

Avg Target (Last Quarter)$109.86
Analysts Covering (Quarter)7
Avg Target (Last Year)$102.33
Analysts (Year)9

Leadership & Governance

CEODavid M. Demski · 2 years
CEO Ownership2.5%
Compensation90% performance-based
Insider ActivitySelling
Capital AllocationROIC 7.6% vs WACC 10.4%
Earnings Beat Rate85% (19/22)

◆ Company Profile

Globus Medical, Inc. , a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally.

CEO
Keith W. Pfeil
Employees
5300
Headquarters
Audubon, PA, US
IPO Date
August 3, 2012
Exchange
NYSE

◆ Related Companies in Our Universe

Other Healthcare companies scored by the Crucible:

ADBE81.8A-NICE80.7A-DECK79.9A-INTU79.9A-EXEL78.3A-MTCH78.2A-TTD78.0B+
MethodologyAll ScoresCrucible BriefsPerformance@KaladinCI

Analysis conducted March 7, 2026 based on most recent SEC filings. Updated quarterly, after new SEC filings.

Point-in-time fundamental analysis. Not investment advice. Scores reflect company quality and valuation at time of analysis and may not reflect current market conditions.

© 2026 Kaladin Capital Intelligence — Conviction Through Scrutiny